JPWO2021126977A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021126977A5 JPWO2021126977A5 JP2022537007A JP2022537007A JPWO2021126977A5 JP WO2021126977 A5 JPWO2021126977 A5 JP WO2021126977A5 JP 2022537007 A JP2022537007 A JP 2022537007A JP 2022537007 A JP2022537007 A JP 2022537007A JP WO2021126977 A5 JPWO2021126977 A5 JP WO2021126977A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- atrasentan
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 78
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims description 46
- 229950010993 atrasentan Drugs 0.000 claims description 46
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 34
- 206010021263 IgA nephropathy Diseases 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 32
- 210000003584 mesangial cell Anatomy 0.000 claims description 28
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 11
- 208000033626 Renal failure acute Diseases 0.000 claims description 11
- 201000011040 acute kidney failure Diseases 0.000 claims description 11
- 208000012998 acute renal failure Diseases 0.000 claims description 11
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 10
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- 230000003176 fibrotic effect Effects 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000006750 hematuria Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000001474 proteinuria Diseases 0.000 claims description 5
- 206010001580 Albuminuria Diseases 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 53
- 210000002700 urine Anatomy 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 3
- 238000011862 kidney biopsy Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 230000036454 renin-angiotensin system Effects 0.000 claims 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 208000022182 gross hematuria Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 208000022204 primary glomerular disease Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- -1 cPLA 2 Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 7
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 5
- 206010070737 HIV associated nephropathy Diseases 0.000 description 5
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102100031168 CCN family member 2 Human genes 0.000 description 3
- 101150074775 Csf1 gene Proteins 0.000 description 3
- 102100028121 Fos-related antigen 2 Human genes 0.000 description 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 3
- 101001059934 Homo sapiens Fos-related antigen 2 Proteins 0.000 description 3
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 3
- 101710091439 Major capsid protein 1 Proteins 0.000 description 3
- 101150010110 Map3k8 gene Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 2
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 2
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 description 2
- 108700040066 Argininosuccinate lyases Proteins 0.000 description 2
- 101150025804 Asl gene Proteins 0.000 description 2
- 101150012131 BTG1 gene Proteins 0.000 description 2
- 101150068685 BTG2 gene Proteins 0.000 description 2
- 101150102665 CCL20 gene Proteins 0.000 description 2
- 101150031350 Cxcl2 gene Proteins 0.000 description 2
- 102100020743 Dipeptidase 1 Human genes 0.000 description 2
- 101150049876 EDN1 gene Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 description 2
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 2
- 101000932213 Homo sapiens Dipeptidase 1 Proteins 0.000 description 2
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101150012417 IL1B gene Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 101100206736 Mus musculus Tiam1 gene Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 101150045905 NFAT5 gene Proteins 0.000 description 2
- 101150022485 Nfkb1 gene Proteins 0.000 description 2
- 101150091206 Nfkbia gene Proteins 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101150075616 Nr4a3 gene Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 101150117945 PDGFB gene Proteins 0.000 description 2
- 101150038994 PDGFRA gene Proteins 0.000 description 2
- 101150046396 PIK3R1 gene Proteins 0.000 description 2
- 101150093295 Pla2g4a gene Proteins 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 101150054980 Rhob gene Proteins 0.000 description 2
- 108060007758 SLC6A19 Proteins 0.000 description 2
- 102000005025 SLC6A19 Human genes 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
- 101710181917 Serine proteinase inhibitor 1 Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 101150008094 per1 gene Proteins 0.000 description 2
- 108091011896 CSF1 Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102100031615 Ciliary neurotrophic factor receptor subunit alpha Human genes 0.000 description 1
- 101150017672 Cntfr gene Proteins 0.000 description 1
- 102100029707 DnaJ homolog subfamily B member 4 Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 101150096607 Fosl2 gene Proteins 0.000 description 1
- 102100025626 GTP-binding protein GEM Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000993348 Homo sapiens Ciliary neurotrophic factor receptor subunit alpha Proteins 0.000 description 1
- 101000866008 Homo sapiens DnaJ homolog subfamily B member 4 Proteins 0.000 description 1
- 101000856606 Homo sapiens GTP-binding protein GEM Proteins 0.000 description 1
- 101000886596 Homo sapiens Geminin Proteins 0.000 description 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 1
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 description 1
- 101150029684 IL2RA gene Proteins 0.000 description 1
- 101150047285 Il1r1 gene Proteins 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150088803 NR4A1 gene Proteins 0.000 description 1
- 101150026563 NR4A2 gene Proteins 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 229940058934 aminoquinoline antimalarials Drugs 0.000 description 1
- 150000005010 aminoquinolines Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218275A JP7821870B2 (ja) | 2019-12-17 | 2024-12-12 | アトラセンタンによるｉｇａ腎症を治療する方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949115P | 2019-12-17 | 2019-12-17 | |
| US62/949,115 | 2019-12-17 | ||
| US202063005003P | 2020-04-03 | 2020-04-03 | |
| US63/005,003 | 2020-04-03 | ||
| US202063072699P | 2020-08-31 | 2020-08-31 | |
| US63/072,699 | 2020-08-31 | ||
| US202063084739P | 2020-09-29 | 2020-09-29 | |
| US63/084,739 | 2020-09-29 | ||
| US202063125205P | 2020-12-14 | 2020-12-14 | |
| US63/125,205 | 2020-12-14 | ||
| PCT/US2020/065311 WO2021126977A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218275A Division JP7821870B2 (ja) | 2019-12-17 | 2024-12-12 | アトラセンタンによるｉｇａ腎症を治療する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023507739A JP2023507739A (ja) | 2023-02-27 |
| JPWO2021126977A5 true JPWO2021126977A5 (https=) | 2023-12-26 |
| JP2023507739A5 JP2023507739A5 (https=) | 2023-12-26 |
| JP7624995B2 JP7624995B2 (ja) | 2025-01-31 |
Family
ID=76478538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537007A Active JP7624995B2 (ja) | 2019-12-17 | 2020-12-16 | アトラセンタンによるｉｇａ腎症を治療する方法 |
| JP2024218275A Active JP7821870B2 (ja) | 2019-12-17 | 2024-12-12 | アトラセンタンによるｉｇａ腎症を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218275A Active JP7821870B2 (ja) | 2019-12-17 | 2024-12-12 | アトラセンタンによるｉｇａ腎症を治療する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US20210353593A1 (https=) |
| EP (2) | EP4076652B1 (https=) |
| JP (2) | JP7624995B2 (https=) |
| KR (1) | KR20230015874A (https=) |
| CN (3) | CN116327758A (https=) |
| AU (1) | AU2020404984A1 (https=) |
| BR (1) | BR112022012075A2 (https=) |
| CA (1) | CA3161516A1 (https=) |
| DK (1) | DK4076652T3 (https=) |
| FI (1) | FI4076652T3 (https=) |
| HR (1) | HRP20260121T1 (https=) |
| IL (1) | IL293921A (https=) |
| LT (1) | LT4076652T (https=) |
| MX (1) | MX2022007471A (https=) |
| PH (1) | PH12022551456A1 (https=) |
| PL (1) | PL4076652T3 (https=) |
| PT (1) | PT4076652T (https=) |
| RS (1) | RS67746B1 (https=) |
| SI (1) | SI4076652T1 (https=) |
| TW (1) | TWI875895B (https=) |
| WO (1) | WO2021126977A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230015874A (ko) | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| CN114910647A (zh) * | 2022-05-07 | 2022-08-16 | 浙江大学 | 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用 |
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| JP2025517355A (ja) * | 2022-05-19 | 2025-06-05 | チヌーク セラピューティクス，インコーポレイテッド | アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| WO2024076177A1 (ko) * | 2022-10-05 | 2024-04-11 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물 |
| EP4608396A1 (en) * | 2022-10-28 | 2025-09-03 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| JP2025536433A (ja) | 2022-11-07 | 2025-11-05 | サンレノ セラピューティクス （シャンハイ） リミテッド | ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ |
| WO2025261457A1 (zh) * | 2024-06-21 | 2025-12-26 | 深圳信立泰药业股份有限公司 | 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5236940A (en) | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US20020062121A1 (en) | 1995-05-16 | 2002-05-23 | Karl Tryggvason | Perfusion apparatus and methods for pharmaceutical delivery |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US20040191774A1 (en) | 2001-09-11 | 2004-09-30 | Moskowitz David W | Endothelin-1 promoter polymorphism |
| WO2003080038A1 (en) | 2002-03-22 | 2003-10-02 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for kidney disease |
| AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US20030229906A1 (en) | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| DE602005022871D1 (de) | 2004-06-07 | 2010-09-23 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| CA2578824A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| US8231907B2 (en) | 2006-03-21 | 2012-07-31 | Morehouse School Of Medicine | Nanoparticles for delivery of active agents |
| AU2007230580A1 (en) * | 2006-03-27 | 2007-10-04 | Genentech, Inc. | Methods for treating kidney disorders |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| NZ578164A (en) | 2007-01-16 | 2011-12-22 | Musc Found For Res Dev | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| AU2008282773B8 (en) | 2007-07-31 | 2013-03-07 | Gilead Sciences, Inc. | Metabolites and derivatives of ambrisentan |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| US20120083421A1 (en) | 2008-10-16 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) |
| EP3708163A1 (en) | 2009-03-31 | 2020-09-16 | Ligand Pharmaceuticals, Inc. | Use of sparsentan for the treatment of chronic inflammatory diseases |
| EP2509594A1 (en) | 2009-12-09 | 2012-10-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| US9365445B2 (en) | 2010-07-28 | 2016-06-14 | Nippon Electric Glass Co., Ltd. | Method for producing phosphor-encapsulating capillary tube, phosphor-encapsulating capillary tube, wavelength-converting member, and method for producing wavelength-converting member |
| US20160015701A1 (en) * | 2013-03-08 | 2016-01-21 | Abbive Inc. | Methods of Treating Acute Kidney Injury |
| KR20160003128A (ko) | 2013-04-30 | 2016-01-08 | 애브비 인코포레이티드 | 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법 |
| CA2916033C (en) * | 2013-07-08 | 2022-08-23 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| JP2017534634A (ja) * | 2014-11-07 | 2017-11-24 | アッヴィ・インコーポレイテッド | 体液貯留の予測因子を使用してｃｋｄを処置する方法 |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170014386A1 (en) | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| MA43260A (fr) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| US10736960B2 (en) | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JP2019530713A (ja) * | 2016-10-13 | 2019-10-24 | レトロフィン， インコーポレイテッド | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| MX2021014356A (es) | 2016-11-23 | 2022-11-24 | Chemocentryx Inc | Metodo para tratar glomeruloesclerosis segmentaria focal. |
| AU2018347361A1 (en) | 2017-10-11 | 2020-04-30 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
| KR20260037123A (ko) | 2017-11-30 | 2026-03-17 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용 |
| KR20230015874A (ko) * | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| US20220304979A1 (en) | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| JP2023521169A (ja) | 2020-04-10 | 2023-05-23 | チヌーク セラピューティクス，インコーポレイテッド | 糖尿病性腎疾患の処置方法 |
| US20220243994A1 (en) | 2021-02-04 | 2022-08-04 | Northrop Grumman Systems Corporation | Metal woodpile capillary wick |
-
2020
- 2020-12-16 KR KR1020227024511A patent/KR20230015874A/ko active Pending
- 2020-12-16 CA CA3161516A patent/CA3161516A1/en active Pending
- 2020-12-16 HR HRP20260121TT patent/HRP20260121T1/hr unknown
- 2020-12-16 WO PCT/US2020/065311 patent/WO2021126977A1/en not_active Ceased
- 2020-12-16 MX MX2022007471A patent/MX2022007471A/es unknown
- 2020-12-16 RS RS20260142A patent/RS67746B1/sr unknown
- 2020-12-16 LT LTEPPCT/US2020/065311T patent/LT4076652T/lt unknown
- 2020-12-16 PH PH1/2022/551456A patent/PH12022551456A1/en unknown
- 2020-12-16 CN CN202310043260.6A patent/CN116327758A/zh active Pending
- 2020-12-16 JP JP2022537007A patent/JP7624995B2/ja active Active
- 2020-12-16 AU AU2020404984A patent/AU2020404984A1/en active Pending
- 2020-12-16 PT PT209035336T patent/PT4076652T/pt unknown
- 2020-12-16 EP EP20903533.6A patent/EP4076652B1/en active Active
- 2020-12-16 CN CN202310043259.3A patent/CN116173014A/zh active Pending
- 2020-12-16 TW TW109144568A patent/TWI875895B/zh active
- 2020-12-16 IL IL293921A patent/IL293921A/en unknown
- 2020-12-16 DK DK20903533.6T patent/DK4076652T3/da active
- 2020-12-16 BR BR112022012075A patent/BR112022012075A2/pt unknown
- 2020-12-16 EP EP25219043.4A patent/EP4710928A3/en active Pending
- 2020-12-16 SI SI202030727T patent/SI4076652T1/sl unknown
- 2020-12-16 CN CN202080007568.XA patent/CN113272013A/zh active Pending
- 2020-12-16 FI FIEP20903533.6T patent/FI4076652T3/fi active
- 2020-12-16 PL PL20903533.6T patent/PL4076652T3/pl unknown
-
2021
- 2021-06-30 US US17/363,604 patent/US20210353593A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/826,753 patent/US20220304978A1/en not_active Abandoned
- 2022-05-27 US US17/826,843 patent/US11491137B2/en active Active
- 2022-05-27 US US17/826,832 patent/US20220288026A1/en not_active Abandoned
- 2022-08-16 US US17/888,766 patent/US12582631B2/en active Active
-
2023
- 2023-07-18 US US18/223,340 patent/US11998526B2/en active Active
- 2023-07-18 US US18/223,290 patent/US20230355579A1/en not_active Abandoned
- 2023-07-18 US US18/223,355 patent/US12121509B2/en active Active
- 2023-11-29 US US18/523,609 patent/US12521369B2/en active Active
-
2024
- 2024-09-13 US US18/884,802 patent/US20250281454A1/en active Pending
- 2024-12-12 JP JP2024218275A patent/JP7821870B2/ja active Active
- 2024-12-20 US US18/990,351 patent/US12370174B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Breedveld et al. | Leflunomide: mode of action in the treatment of rheumatoid arthritis | |
| US20240207269A1 (en) | Uses of heterocyclic inhibitors of erk1/2 | |
| JP5936628B2 (ja) | ｍＴＯＲ／ＪＡＫ阻害剤併用療法 | |
| Dueñas-González et al. | The prince and the pauper. A tale of anticancer targeted agents | |
| JPWO2021126977A5 (https=) | ||
| CN116173014A (zh) | 用阿曲生坦治疗IgA肾病的方法 | |
| EP2076266A2 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| Oblak et al. | Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double‐blind, randomized controlled trial | |
| JP2007526882A (ja) | リンパ球性白血病を治療するためのロスコビチンの使用 | |
| CN114796228A (zh) | 一种吡啶并[1,2-a]嘧啶酮化合物的应用 | |
| De Brito et al. | Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease | |
| JP7709959B2 (ja) | 連続的な治療設定における免疫チェックポイント阻害剤に対する患者の応答を高めるためのｆｇｆｒ遺伝子改変癌におけるｆｇｆｒ阻害剤の使用 | |
| US20150216865A1 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder | |
| Campione et al. | Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients | |
| JP2025536290A (ja) | Ｗｎｔ経路腫瘍抑制因子に突然変異を有する癌の治療 | |
| AU2019260905A1 (en) | Methods and compositions for reducing risk of relapse and prolonging survival in acute myeloid leukemia | |
| CN117561062A (zh) | 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法 | |
| WO2023044065A1 (en) | Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy | |
| RU2855917C1 (ru) | Сатраплатин для применения при лечении лимфоидных неоплазм | |
| US12570664B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
| Chay et al. | A Systematic Review of the Use of Janus Kinase Inhibitors in Large Vessel Vasculitis. | |
| Sharma et al. | INVA8001, a Novel and Highly Selective Chymase Inhibitor, Ameliorates Liver Inflammation, Fibrosis, and Hyperplasia in Mdr2 Knockout Mice | |
| RU2343908C1 (ru) | Средство для профилактики и лечения алкоголизма и способ его применения | |
| Koh et al. | Bisphosphonates as a tacrolimus-sparing strategy in kidney transplantation: insights from a retrospective analysis | |
| CN120752038A (zh) | 瑞普替尼治疗胃肠道基质瘤的方法 |